ArticleAmerican journal of clinical pathology2026
Impact of tumor budding on recurrence risk prediction in stage I-III colorectal cancer: a Swedish cohort study.
Article in American journal of clinical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
objectivesTumor budding is an emerging micromorphologic predictor of recurrence in localized colorectal cancer (CRC). Whether its addition to established CRC recurrence risk factors routinely assessed in clinical practice improves prediction accuracy remains unclear.
methodsThis study included patients with stage I through III CRC. A detailed micromorphologic assessment was performed for each case according to protocol, using hematoxylin-eosin-stained slides. Clinical characteristics, including treatment and follow-up data, were extracted from patient records. Two logistic regression models were devised to assess recurrence risk, both including established recurrence risk factors chosen a priori. One model also included tumor budding as a dichotomous variable. Receiver operating characteristic curves were used to evaluate and compare the prognostic performance of each model.
resultsOf the 1083 cases of CRC included in the study, 441 (41%) displayed tumor budding. Tumor budding was more common in right-sided colon cancer, following a right-to-left gradient in the bowel. It occurred more frequently in patients with adverse prognostic factors and in patients presenting with surgical emergencies necessitating emergency resection. Median follow-up time was 4.3 years. Tumor budding was strongly associated with disease recurrence in univariate analysis, but the association was not maintained in multivariate analysis. There was no statistically significant difference between the areas under the curve of the 2 models.
conclusionsTumor budding did not substantially contribute to recurrence risk prediction in this study. Further research exploring the association between tumor budding, established recurrence risk factors, and CRC prognosis is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.